Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1635-1643

  Laxton, Ross C ^a   Popov, Sergey ^b,c   Doey, Lawrence ^a   Jury, Alexa ^b,c   Bhangoo, Ranj ^a   Gullan, Richard ^a   Chandler, Chris ^a   Brazil, Lucy ^d   Sadler, Gill ^e   Beaney, Ron ^d   Sibtain, Naomi ^a   King, Andrew ^a   Bodi, Istvan ^a   Jones, Chris ^b,c   Ashkan, Keyoumars ^a   Al Sarraj, Safa ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Divisions of Molecular Pathology   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL STRUCTURE; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENDER; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE CELL DIFFERENTIATION; OLIGODENDROGLIA; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT;

1P/19Q; GLIOBLASTOMA WITH AN OLIGODENDROGLIAL COMPONENT; HISTOPATHOLOGY; IDH1; MGMT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OLIGODENDROGLIOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84891848472     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not125     Document Type: Article

References (28)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC; 2007.
2. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-2606.
3. Kraus JA, Lamszus K, Glesmann N, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathologica. 2001;101(4):311-320.
4. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: A pathological and molecular study. J Neuropathol Exper Neurol. 2001;60(9):863-871.
5. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S. Histological indicators of prognosis in glioblastomas: Retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology. 2004;44(6):555-560.
6. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exper Neurol. 2006;65(9):846-854.
7. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Rad Oncol Biol Phys. 2000;48(3):825-830.
8. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23(4):360-364.
9. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990; 27(5):573-574.
10. Salvati M, Formichella AI, D'Elia A, et al. Cerebral glioblastoma with oligodendrogliomal component: Analysis of 36 cases. J Neuro-Oncol. 2009;94(1):129-134.
11. Miller CR, DunhamCP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol. 2006;24(34): 5419-5426.
12. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of theDNArepairgeneO-6-methylguanine-DNAmethyltransferaseby promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793-797.
13. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-254.
14. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathologica. 2009;118(5):599-601.
15. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathologica. 2009;118(4):469-474.
16. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in lowgrade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17(13): 4588-4599.
17. Mann HB, Whitney DR. On a test of whether one of 2 random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1): 50-60.
18. Donahue B, Scott CB, Nelson JS, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of Radiation Therapy Oncology Group 83-02. Int J Rad Oncol Biol Phys. 1997;38(5):911-914.
19. Green RE, Krause J, Ptak SE, et al. Analysis of one million base pairs of neanderthal DNA. Nature. 2006;444(7117):330-336.
20. Ichimura K,Vogazianou AP, Liu L, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27(14):2097-2108.
21. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exper Neurol. 2002;61(4):321-328.
22. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006;106(10):2218-2223.
23. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Rad Oncol Biol Phys. 2005;63(3):704-710.
24. Gadji M, Fortin D, Tsanaclis AM, Drouin R. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet. 2009;194(1):12-22.
25. Scheie D, Meling TR, Cvancarova M, et al. Prognostic variables in oligodendroglial tumors: A single-institution study of 95 cases. Neuro- Oncology. 2011;13(11):1225-1233.
26. vonDeimling A, KorshunovA, HartmannC. Thenextgeneration of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011;21(1):74-87.
27. Hegi ME, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352(10): 997-1003.
28. Parsons DW, Jones S, Zhang XS, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.